Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women

Archives of Gynecology and Obstetrics

Volumn 281, Issue 5, 2010, Pages 857-864

  Bingol, Banu ^a   Gunenc, Ziya ^b   Yilmaz, Murat ^a   Biri, Aydan ^c   Tiras, Bülent ^c   Güner, Haldun ^c  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b MALTEPE UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Carbohydrate and lipid metabolism; Cardiovascular risk; Fibrinogen; Homocysteine; Hormone replacement therapy

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL PLUS NORETHISTERONE ACETATE; FIBRINOGEN; HEMOGLOBIN A1C; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; FEMALE; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; LIPID METABOLISM; ORAL GLUCOSE TOLERANCE TEST; POSTMENOPAUSE; WAIST HIP RATIO;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPOPROTEINS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; RISK FACTORS;

EID: 77950630113     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1169-y     Document Type: Article

References (32)

1. Stramba-Badiale M (2009) Postmenopausal hormone therapy and the risk of cardiovascular disease. J Cardiovasc Med (Hagerstown) 10(4):303-309
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooper-berg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
4. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, HERS Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49-57 (Pubitemid 34705518)
5. Zegura B, Keber I, Sebestjen M, Koenig W (2003) Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 168:123-129 (Pubitemid 36555819)
6. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237-242
7. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843 (Pubitemid 30165206)
8. Christodoulakos GE, Panoulis CPC, Lambrinoudaki IV, Dendrinos SG, Rizos DA, Creatsas GC (2004) Effect of hormone replacement therapy and tibolone on serum total homocysteine levels in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 112:74-77
9. Li C, Samsioe G, Borgfeldt C, Bendahl PO, Wilawan K, Aberg A (2003) Low-dose hormone therapy and carbohydrate metabolism. Fertil Steril 79:550-555
10. Friedewald WT, Levy RI, Friedrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifugate. Clin Chem 18:499-502
11. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Writing Group for the PEPI Trial. JAMA 273:199-208
12. Cooper BC, Burger NZ, Toth MJ, Cushman M, Sites CK (2007) Insulin resistance with hormone replacement therapy: Associations with markers of inflammation and adiposity. Am J Obstet Gynecol 196(2): 123-127
13. Kimmerle R, Heinemann L, Heise T, Bender R, Weyer C, Hirsch-berger S, Berger M (1999) Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 6:36-42
14. Vehkavaara S, Westerbacka J, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Yki-Jarvinen H (2000) Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresis-tance and resistance vessel function in healthy postmenopausal women. J Clin Endocrinol Metab 85:4663-4670
15. Villa P, Sagnella F, Perri C, Suriano R, Costantini B, Macri F, Ricciardi L, Lanzone A (2008) Low and standard-estrogen dosage in oral therapy: Dose dependent effects on insulin and lipid metabolism in healthy postmenopausal women. Climacteric 11:498-508
16. The Expert Committee on the diagnosis and classification of diabetes mellitus (2003) Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:3160-3167
17. Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM, Women's Health Initiative (2004) The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81:1498-1501
18. Sare GM, Gray LJ, Bath PM (2008) Association between hormone replacement therapy and subsequent arterial and venous vascular events: A meta-analysis. Eur Heart J 29:2031-2041
19. Farag NH, Barshop BA, Mills PJ (2003) Effects of estrogen and psychological stress on plasma homocysteine levels. Fertil Steril 79:256-260
20. Bayrak A, Aldemir DA, Bayrak T, Corakci A, Dursun P (2006) The effects of hormone replacement therapy on the levels of serum lipids, apoprotein A1, apoprotein B and lipoprotein (a) in Turkish postmenopausal women. Arch Gynecol Obstet 274:289-296
21. Godsland IF (2001) Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000. Fertil Steril 75:898-915
22. Perry W, Wiseman RA (2002) Combined oral estradiol valerate- norethisterone treatment over 3 years in postmenopausal women: Effect on lipids, coagulation factors, hematology and biochemistry. Maturitas 42:157-164
23. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP (2002) A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 77:945-951
24. Kernohan AF, Sattar N, Hilditch T, Cleland SJ, Small M, Lumsden MA, Connell JM, Petrie JR (2007) Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol 66(1):27-34
25. Gram J, Bladbjerg EM, Moller L, Sjol A, Jespersen J (2000) Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Intern Med 247:205-212
26. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-733
27. Ylikorkala O, Evio S, Valimaki M, Tiitinen A (2003) Effects of hormone therapy and alendronate on C-reactive protein, E-selec-tin, and sex hormone-binding globulin in osteoporotic women. Fertil Steril 80:541-545
28. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH (1999) Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281:1817-1821
29. Evio S, Tiitinen A, Turpeinen U, Ylikorkala O (2000) Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril 74:1080-1083
30. Bruschi F, Pino DD, Fiore V, Parazzini F, Di Pace R, Cesane BM, Melotti D, Crosignani PG (2004) Effect of oral or transdermal hormone replacement therapy on homocysteine levels; a randomized clinical trial. Maturitas 48:33-38
31. Yilmazer M, Fenkci V, Fenkci S, Sonmezer M, Aktepe O, Altindis M, Kurtay G (2003) Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. Maturitas 46:245-253
32. Norris LA, Joyce M, O'Keeffe N, Sheppard BL, Bonnar J (2002) Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 43:125-133